MaaT Pharma received authorizations from French and German regulatory authorities to initiate its Phase 2b clinical trial evaluating MaaT033 in improving survival in patients receiving allogeneic
This randomized clinical trial examines whether systematic 4-factor prothrombin complex concentrate administration combined with a ratio-based transfusion proto
/PRNewswire/ Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies long-term.
Domain Therapeutics to progress into clinical trials with its EP4R antagonist DT-9081 in solid tumors Clinical trial applications accepted in France and.